An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels 10 times greater than is seen in people who have recovered from COVID-19 infections.
Hundreds of candidate vaccines for COVID-19 are in development around the world. Many require large doses, complex manufacturing, and cold-chain shipping and storage. An ultrapotent vaccine that is safe, effective at low doses, simple to produce and stable outside of a freezer could enable vaccination against COVID-19 on a global scale.
Compared to vaccination with the soluble SARS-CoV-2 Spike protein, on which many leading COVID-19 vaccine candidates are based, the new nanoparticle vaccine produced 10 times more neutralizing antibodies in mice, even at a sixfold lower dose. The data also show a strong B-cell response after immunization, which can be critical for immune memory and a durable vaccine effect.